Prohost Letter #407
AT A GLANCE -
Firms Added to Prohost Portfolio
PROHOST IS PICKING NEUROCRINE BIOSCIENCES
On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD), we posted an article titled “Time for Transformation and Achievements”. In the article, we stated that Neurocrine Sciences Ingrezza will highlight Neurocrine Biosciences and its Scientists, based on our persuasion that phase 3 trial results demonstrated the drug . . .
This content is for paid subscribers.
Prohost Letters April 20, 2017